Acquisitions (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of proforma results

	Three Months Ended
	March 31,
	2017
Revenue	$	34,289
Net loss		(3,338)
Net loss per share attributable to common stockholders, basic and diluted		(0.20)

SinfoniaRx

Schedule of purchase price consideration

Cash consideration at closing, net of post-closing adjustments	$	34,492
Stock consideration at closing		11,541
Estimated fair value of contingent consideration		38,092
Total fair value of acquisition consideration	$	84,125

Schedule of allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities

		Preliminary
		Purchase Price
Cash	$	218
Accounts receivable		8,309
Prepaid expenses and other current assets		1,056
Property and equipment		1,419
Other assets		127
Trade name		4,776
Developed technology		13,291
Client relationships		20,265
Non-competition agreement		4,752
Goodwill		52,898
Total assets acquired	$	107,111
Accrued expenses and other liabilities		(3,819)
Trade accounts payable		(8,868)
Debt assumed		(675)
Deferred income tax liability, net		(9,624)
Total purchase price, including contingent consideration of $38,092	$	84,125